BioSpecifics Technologies (NASDAQ:BSTC)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Tuesday. They currently have a $65.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 49.63% from the stock’s previous close.
BSTC has been the subject of several other reports. Zacks Investment Research raised shares of BioSpecifics Technologies from a “hold” rating to a “strong-buy” rating and set a $50.00 price target for the company in a research note on Monday, January 15th. lowered their price target on shares of BioSpecifics Technologies from $72.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 15th.
Shares of BioSpecifics Technologies (NASDAQ BSTC) opened at $43.44 on Tuesday. The firm has a market cap of $312.16, a price-to-earnings ratio of 27.31 and a beta of 1.55. BioSpecifics Technologies has a one year low of $38.05 and a one year high of $58.79.
COPYRIGHT VIOLATION WARNING: “BioSpecifics Technologies (BSTC) Rating Reiterated by HC Wainwright” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/03/13/hc-wainwright-reaffirms-buy-rating-for-biospecifics-technologies-bstc.html.
BioSpecifics Technologies Company Profile
BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.